BSX
Boston Scientific Corp.
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Best Medical Devices Stocks 2026 →
Boston Scientific (BSX) Stock: Buy, Sell, or Hold?
$45.13
+0.43 (+0.96%)
â˛
5d:
-1.51%
30d:
+4.2%
90d:
-12.69%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Oct 28, 2026
0d
Protect BSX Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (61%)
Quality Score
53/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$42.58 â $45.21
Position: SLIGHTLY HIGH
Forward P/E & Valuation
14.4x
CHEAP
vs 16.9x historical avg
Wall Street Target
$49.60
+9.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$41.68 / $46.97
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: BSX is fairly priced but lacks strong directional signals. At -5.2% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Nov 2, 2026 at $44.32 · last confirmed Nov 9, 2026
Strength: 8.0/10
Get Alerted When BSX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$56.53
Based on 1.4% avg growth
INTRINSIC VALUE TODAY
$35.10
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BSX is currently trading at $45.13, which is considered slightly high relative to its 30-day fair value range of $42.58 to $45.21. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.4) compared to its historical average (16.9). Remarkably, the market is currently pricing in an annual earnings decline of 5.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BSX is in a uptrend. Immediate support is located at $41.67, while resistance sits at $46.97.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BSX is in a uptrend. Immediate support is located at $41.67, while resistance sits at $46.97.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$42.58 -
$45.21
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
Trading Range & Key Levels
30-Day Trading Range
$42.58 -
$45.21
Current vs Trading Range
SLIGHTLY HIGH
Support Level
$41.68
Resistance Level
$46.97
Current Trend
Uptrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding BSX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($49.60)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
14.42
Wall Street Target
$49.60
(+9.9%)
Revenue Growth (YoY)
1.4%
Earnings Growth (YoY)
-21.5%
Profit Margin
16.6%
Valuation Discount vs History
-5.2% cheaper
PE vs Historical
14.4 vs 16.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.2%
(market-implied from PE analysis)
1-Year Target
$42.78
(-5%)
2-Year Target
$40.56
(-10%)
3-Year Target
$38.45
(-15%)
3-Yr Target (if PE normalizes)
(PE: 14â17)
$45.08
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: -1.3%)
$59.78
(+33%)
Base:
(SPY PE: 14.4, Growth: -1.3%)
$43.39
(-4%)
Bear:
(PE: 12.3, Growth: -1.3%)
$36.89
(-18%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.86 | Current EPS (TTM): $2.37
Bull Case
$64.95
(+44%)
Analyst growth 32.1%, PE expands to 20.8
Base Case
$59.05
(+31%)
Market implied 32.1%, PE stable at 18.9
Bear Case
$30.40
(-33%)
Severe decline -20.0%, PE contracts to 16.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.4 to 16.9
Stabilization Target:
$52.91
(+17.2%)
PE Expansion Potential:
+17.2%
Share BSX Analysis
Share this live BSX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (BSX)
Bullish
4 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
3 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Boston Scientific (BSX) faced multiple FDA-listed Class II recalls of its Neuromodulation system and Direxion Torqueable Microcatheters in 2026, which could impact patient safety and physician trust. Wall Street analysts, however, remain bullish on BSX following favorable news regarding the WATCHMAN trial.
Key Retail Themes:
FDA Class II recalls of Neuromodulation system and Direxion Torqueable Microcatheters
Bullish sentiment from Wall Street analysts following WATCHMAN trial news
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 8:04 AM ET
Data refreshes hourly during market hours. Next update: 9:04 AM
Data refreshes hourly during market hours. Next update: 9:04 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BSX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$98 | 52 HOLD |
|
MDT
Medtronic PLC |
BUY
30 analysts |
$105 | 39 SELL |
|
PODD
Insulet Corporation |
BUY
26 analysts |
$178 | 45 HOLD |
|
IRTC
iRhythm Technologies Inc |
STRONG BUY
16 analysts |
$166 | 46 HOLD |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 49 HOLD |
Advanced BSX Option Strategies
Professional options setups generated by AI based on today's BSX price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive BSX Research Pages
